Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.
Authors: Budde Lihua Elizabeth , Deisher Theresa , Stevens Don A. , Schiller Gary J. , Tarantolo Stefano R. , Ramaekers Ryan C. , Jarzyna Peter , Sawas Spencer , Mittal Sandeep 
Published: June 2024

7077 Background: In 2022, the majority of new cancer drugs in clinical development are aimed at targets that are already saturated with approved drugs1. This is of concern to patients, payers, sponsor/investors, and regulatory agencies. AVM0703 activates a unique immune response mobilizing an endogenous gamma delta TCR+ and invariant TCR+ bispecific Natural Killer T-like cell (γδTCR+iTCR+NKT) (PCT/US21/19773), that has demonstrated clinical anti-cancer activity against a variety of solid and blood cancers. The potential for AVM0703 to fill a gap in the “no-option” R/R NHL treatment landscape led to the launch of the AVM0703-001 clinical trial (The OPAL Study, NCT04329728). 1) Fougner C et al. Herding in the drug development pipeline. Nat Rev Drug Discov. 2023 Aug;22(8):617-618. Methods: An open-label phase 1 trial evaluating the safety and preliminary efficacy of AVM0703 was completed in patients with hematological malignancies. AVM0703 was administered as a single intravenous (IV) infusion to patients enrolled into a 3+3 dose escalation design. Consolidation therapy of investigator’s choice was allowed, preferably 28 days after AVM0703. For each cohort, 3-6 patients were treated, and dose escalation permitted only after the cohort completed a 7-day dose limiting toxicity (DLT) assessment period with no more than 1 DLT. Patients ≥12 years and >40 kg diagnosed with WHO classified lymphoid neoplasms with R/R disease ineligible for transplant or CAR-T were included. The database has not been formally locked and a cutoff date of Dec 13, 2023, is used for presentation of these Phase 1 results. Results: In summary, 17 patients, 39-86 years of age (median 64) with a median of 4 prior lines (range: 1 to 10) received AVM0703 at 6, 9, 12, 18 and 21 mg/kg. Fifteen (88%) were poor prognosis and 4 had CNS involvement. Only 13 of 17 (76.5%) experienced study-drug related adverse events (AEs) during the DLT period; 15 AEs were grade 1 (78.9%), 2 were grade 2 (10.5%), and 2 were grade 3 (10.5%). The most common AEs were insomnia (N=5), hyperglycemia (N=3), and pruritis (N=2). The total number of All-grade TEAEs recorded in 17 patients was 114 within 30 days post dose, with 98.2% of grades 1-3. Median overall survival (OS) in all dose cohorts was 13.3 months, with 8 of 17 patients alive as of 13 Dec 2023. The recommended Phase 2 dose (RP2D) was determined as 18 mg/kg. For the 18 mg/kg group (N=6), long term durable responses were obtained in 66% (3 CR, 1 PR) with an additional patient converting to late CR, nine months survival was 100%, and median OS has not been reached with follow up between 15.9 and 27.8 months (83% still alive). No safety signals have been identified. Conclusions: RP2D AVM0703, with consolidation therapy at day 28 median (range 7 to 240 days) showed no concerning safety signals and promising long-term survival. Clinical trial information: NCT04329728 .